肝癌TACE还是HAIC?
Treatment of hepatocellular carcinoma:TACE or HAIC?
杜楠 1王英 1李文涛1
作者信息
- 1. 200032 上海 复旦大学附属肿瘤医院介入治疗科;复旦大学上海医学院肿瘤学系
- 折叠
摘要
经导管动脉化疗栓塞术(TACE)是目前中晚期不可切除肝癌的常用治疗方法.近年来,国内奥沙利铂+氟尿嘧啶+亚叶酸钙(FOLFOX)方案的肝动脉灌注化疗(hepatic artery infusion chemotherapy,HAIC)已用于治疗中晚期肝癌.HAIC联合应用分子靶向药物和(或)免疫检查点抑制剂,取得了令人鼓舞的成果.该文介绍了 TACE和HAIC的理论基础、发展史及研究进展,分析比较二者的疗效和不良反应,以期为中晚期肝癌患者选择治疗时机及治疗方案提供参考.
Abstract
At present,transcatheter arterial chemoembolization(TACE)is a common treatment for advanced unresectable hepatocellular carcinoma(HCC).In recent years,hepatic artery infusion chemotherapy(HAIC)with oxaliplatin plus fluorouracil and leucovorin(FOLFOX)regimen has been used in the treatment of advanced HCC in China.HAIC in combination with molecular targeted drugs and/or immune checkpoint inhibitors has yielded encouraging results.This paper aims to describe the theoretical basis,development history and research progress of TACE and HAIC,to analyze and compare the efficacy and adverse events of TACE and HAIC,so as to provide a reference for the choice of treatment timing and therapeutic regimen for patients with advanced HCC.
关键词
肝细胞癌/经导管动脉化疗栓塞术/肝动脉灌注化疗/分子靶向药物治疗Key words
hepatocellular carcinoma/transcatheter arterial chemoembolization/hepatic artery infusion chemotherapy/molecular targeted drug therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据